1) 日本泌尿器科学会, 編. 男性下部尿路症状・前立腺肥大症診療ガイドライン. 東京 : リッチヒルメディカル ; 2017.
4) Yoshida M, Takeda M, Gotoh M, et al. Vibegron, a novel potent and selective β(3) -adrenoreceptor agonist, for the treatment of patients with overactive bladder : A randomized, double-blind, placebo-controlled phase 3 study. Eur Urol. 2018 ; 73 : 783-90.
5) Ichihara K, Masumori N, Fukuta F, et al. A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction. J Urol. 2015 ; 193 : 921-6.
6) Kakizaki H, Lee KS, Yamamoto O, et al. Mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms : A randomized, placebo-controlled study (MATCH). Eur Urol Focus. 2020 ; 6 : 729-37.